Background. The beneficial effects of glycemic control on both survival and function of transplanted kidneys in patients with type 1 diabetes mellitus (T1DM) and end-stage renal disease (ESRD) have been recognized. Methods. Herein, we present the clinical outcome of a single-center pilot trial of islet after kidney (IAK) transplantation in seven patients with T1DM. The immunosuppression protocol for the kidney graft was converted to sirolimusϩtacrolimus regimen 6 months before islet transplantation to exclude negative effects on kidney graft function. Primary endpoint was achievement of insulin independence after transplantation. Clinical outcome, metabolic control, severe hypoglycemia, kidney function, Quality of Life (QOL) psychometric measures, and adverse events were monitored. Results. Seven patients showed graft function with improved metabolic control (A1c, fasting glycemia, and metabolic tests) after IAK (14,779Ϯ3,800 IEQ/kg). One-year insulin independence was 30% with persistent graft function in 86% (C-peptide-positive). A1c reduction was 1.95Ϯ0.31% from baseline (PϽ0.0001). No episodes of severe hypoglycemia were observed, even after resuming insulin. The direct consequence of these benefits was a significant improvement in diabetes QOL. Adverse events included procedure-related pleural effusion (nϭ2), cholecystitis (nϭ1), and additional immunosuppression-related, all resolved without sequelae. Kidney function (by estimated glomerular filtration rate) remained stable during follow-up in six of seven patients. Conclusions. Islet transplantation represents a feasible therapeutic option for patients with T1DM bearing a stable kidney allograft. Insulin independence at 1 year is lower than what reported in islet transplant alone. Nevertheless, clear benefits in terms of optimal metabolic control and absence of severe hypoglycemia are invariably present.
T ransplantation of islets of Langerhans allows improving metabolic function and quality of life (QOL) in patients with type 1 diabetes mellitus (T1DM) with unstable control and hypoglycemia unawareness (1) (2) (3) . Promising results have been reported in recipients of solitary islet allografts (islet transplantation alone, ITA) in recent years (4 -10) .
The beneficial effects of glycemic control and ␤-cell replacement therapies on both survival and function of transplanted kidneys in patients with T1DM and end-stage renal disease (ESRD) have been recognized (11) (12) (13) (14) (15) (16) (17) . Initial allogeneic islet transplantation trials in patients with T1DM in 1980s and 1990s were performed in ESRD patients as sequential islet-after-kidney (IAK) or simultaneous islet-kidney (SIK) transplantation (18 -22) . They were aimed at assessing the safety and efficacy of islet transplantation in patients with T1DM already requiring immunosuppression for the kidney graft (19, 22) .
In light of the initial success reported in recipients of sequential ITA under the Edmonton protocol of immunosuppression (4, 10) , a new appealing opportunity emerged for the treatment of patients with T1DM and ESRD by using IAK (23) (24) (25) (26) or SIK (27, 28) . Herein, we present the clinical outcome of a single center IAK transplantation pilot trial.
MATERIALS AND METHODS

Patients
Seven subjects with T1DM received allogeneic islet transplantation as part of a pilot IAK trial (Study ID: 2000/ 0329) at our Center between November 2002 and March 2005 under protocols approved by the Institutional Review Board and Western Institutional Review Board (Olimpia, WA). Informed consent was obtained from all patients. Inclusion criteria: T1DM, stable kidney transplant, age 18 -65 years, negative C-peptide (Ͻ0.3 ng/mL by radioimmune assay) in response to a mixed meal tolerance test (MMTT), stable diabetes complications, and body mass index (BMI) Յ26 kg/m 2 . All patients had history of diabetic nephropathy leading to ESRD for which they had received allogeneic kidney grafts (Table 1) . A stable kidney graft function without episodes of rejection and changes in serum creatinine no more than 0.5 mg/dL from baseline in the previous 6 months was required. 
Pancreatic Islets
Islets were isolated from heart-beating, deceased (cerebral death) human donor pancreata by the automated method (29, 30) and purified using a discontinuous and/or continuous density gradients (31, 32) . Intrahepatic islet transplantation was performed, as previously described (33, 34) .
Immunosuppression
As per protocol, at least 6 months before IAK patients were converted to an immunosuppressive regimen based on sirolimus (S; Rapamune, Wyeth; target trough levels: 10 -12 ng/mL) and tacrolimus (T; Prograf, Astellas; target trough levels: 3-5 ng/mL; Table 1 ).
On a case-by-case discussion with the kidney transplant team, 3 patients remained on low-dose steroids: prednisone (7.5-10 mg/day; Pt. 2 and Pt. 3) or methylprednisolone (2-4 mg/day; Pt. 6; Table 1 ). Two patients were on mycophenolate mofetil (M; MMF; Cellcept, Roche) at 0.5-1.0 g bid, and they remained on it after islet transplantation because of low tolerability of tacrolimus allowing maintenance of lower trough levels.
Induction with daclizumab (D; Zenapax, Roche) was given at 1 mg/kg before each islet infusion and repeated up to 5 doses biweekly and then monthly for 1 year. At the time of islet infusion, administration of antitumor necrosis factor receptor antibody was given to reduce inflammation. Initial patients received 5 mg/kg infliximab (Remicade, Centocor) intravenously before islet infusion. More recent patients received etanercept 50 mg (Enbrel, Amgen-Wyeth) intravenously before each islet infusion followed by subcutaneous 25 mg twice weekly for 2 weeks. Sirolimus trough levels were maintained at 12-15 ng/ml for the first trimester postinfusion, and tapered to 10 -12 ng/mL thereafter.
After IAK, one patient was converted to MMF-sirolimus maintenance because of tacrolimus neurotoxicity. In the case of MMF-related gastrointestinal side-effects, patients were given enteric-coated Mycophenolic Acid (MA; Myfortic, Novartis; 360 -720 mg bid).
Other Treatments
Peritransplant management with low molecular weight heparin starting on the day of islet infusion (Lovenox, SanofiAventis; 30 mg subcutaneously BID for a week). Adjuvant treatment included: pentoxifylline (400 mg PO TID) for the first trimester, vitamins A (25,000U daily), B6 (100 mg/day), C (1,000 mg/day) and E (800 mg/day) for one year. All patients except one were on statins before IAK and continued treatment adjusted according to guidelines (35) .
Cytomegalovirus (CMV) prophylaxis: valgancyclovir (Valcyte ® , Roche) 900 mg PO QD for 3 months, repeated with each islet infusion (36 -38) . Pneumocystis Carinii pneumonia prevention: trimethoprim-sulfametoxazol (400/80 mg; Bactrim single strength, Roche) three times per week.
Patients with anemia received vitamin B12 (100 g/ day), folic acid (400 g/day), and/or oral iron (325 mg/ day), based on clinical judgment. Epoetin-alfa (Procrit; Ortho-Biotech Products) was given by protocol if hemoglobin values were Ͻ10 mg/dL. Severe neutropenia (absolute neutrophil count, ANCϽ500/mm 3 ) was treated with filgrastim (Neupogen ® ; Amgen) at 5 g/kg/day, until ANC reached 10,000/mm 3 .
Islet Graft Function
Monitoring included fingerstick glucose levels, plasma fasting glucose, exogenous insulin requirements, glycated hemoglobin (A1c), basal and stimulated C-peptide, as well as basal C-peptide/glucose ratio (CPGR) (39) . Metabolic tests (baseline and follow-up) included MMTT, intravenous glucose tolerance test (IVGTT), and intravenous arginine stimulation test (7, 19, 39) .
Insulin Independence
A1cՅ6.5% without exogenous insulin administration, and capillary fasting and postprandial blood glucose levels were Յ7.8 mmol/L (140 mg/dL) and Յ10mmol/L (180 mg/ dL), respectively (7, 39) .
Graft Dysfunction
C-peptide-positive recipients having fasting capillary glucose Ͼ7.8 mmol/L and/or postprandial capillary glucose Ͼ10.0 mmol/L in Ն3 occasions in any 7-day period, and this required reintroduction of exogenous insulin therapy (7, 39) .
Graft Failure
Patients having a negative stimulated C-peptide (Ͻ0.3 ng/mL) during MMTT during posttransplant follow-up (22, 39) . Primary endpoint of the study was insulin independence after IAK.
Kidney Function
Before and after IAK we assessed serum creatinine (sCr), estimation of glomerular filtration rate (GFR) calculated using the Modification of Diet in Renal Disease Study Group (MDRD) formula (40); 24-hr proteinuria (Ͼ500 mg/24 hr) and albuminuria (microϭ30 -299 mg/24 hr; macroϾ300 mg/24 hr) on urine collections (41) .
Quality of Life
Standardized psychometric instruments used to evaluate patients at the time of enrolment and at follow-up included the Health Status Questionnaire, HSQ 2.0, and the diabetes quality of life (DQOL), as previously reported (3). In addition, patients underwent psychological evaluation (3).
Immune Monitoring
Absence of sensitization by panel-reactive antibodies (PRA; alloantibodies titers Ͻ20%) was required for inclusion in the study (42) . Minimum donor-recipient matching was negative serum cross-match for T cells and ABO compatibility. Autoantibodies were assessed by radioimmunoassay at the Immunogenetics Laboratory of our Institute (43).
Statistical Analysis
Data was analyzed with repeated measures analysis of variance for each outcome. We used this approach to compare pre-and posttransplant time points with respect to each of the outcomes under consideration. Descriptive statistics were calculated with the Microsoft Excel ® Spreadsheet and graphs generated with SigmaPlot 9.0 (Systat Software, Inc.; San Jose, CA). Analysis was performed with SAS 9.1 software (SAS Institute, Cary, NC). Results are expressed as meanϮSE or SD. Statistical significance was considered for PϽ0.05. A Bonferroni correction was applied for comparisons of QOL scores.
RESULTS
Demographics
Seven subjects were studied (4 males, 3 females; age 45.0Ϯ5.2 years, weight 60.0Ϯ4.6 kg and BMI 22Ϯ1.9 kg/m 2 ; diabetes duration 36Ϯ5 years; Table 1 ). All patients had chronic diabetes complications: retinopathy, neuropathy and ESRD leading to kidney transplantation 6.0Ϯ3.7 years earlier.
Renal function at baseline was sCr 1.4Ϯ0.2 mg/dL and GFR (MDRD) 52Ϯ8.7 mL/min/1.73 m 2 . Normoalbuminuria (nϭ2) micro-albuminuria (nϭ4), macro-albuminuria (nϭ1), and proteinuria (nϭ1) were observed during 24-hr urine collections at baseline (Table 1) .
One patient (Pt. 1) received 2 living-related kidney transplants 20 and 1.5 years before IAK, respectively. Three patients had previously received pancreatic grafts that were lost after 3, 6, and 40 months in patients 7, 3, and 6, respectively (Pt. 7, PAK; pseudo-aneurism of the vascular pedicle; Pt. 3 and Pt. 6 graft rejection; Table 1 ). Kidney grafts were clinically stable and without episodes of rejection in the 6 months preceding islet transplantation.
Islet Transplantation
Islets from 1 (nϭ2), 2 (nϭ3), or 3 (nϭ2) donor pancreata were given as sequential or pooled preparations (Table  2) . Interval between islet infusions was 2.3Ϯ1.2 months (nϭ5). Each infusion contained 6,897Ϯ1,968 IEQ/kg, total tissue volume 2.53Ϯ0.98 mL, purity 73.6Ϯ9.0%, endotoxin Ͻ0.1 EU/kg, viability 92.5Ϯ7.6%, and in vitro glucose-stimulated insulin release of 2.5Ϯ1.4 stimulation index (Table 2) . Collectively, a final islet mass of 14,779Ϯ3,800 IEQ/kg was transplanted per recipient. Portal pressure was stable during and after islet infusion (Table 2) . Portal pressure did not change with subsequent infusions (Table 2) (7, 33, 34) .
All patients received daclizumab induction and immunosuppression maintenance with SϩT without (nϭ4) or with steroids (nϭ3). Two patients received triple therapy (S,T,M; Table 2 ). Induction at the time of each islet infusion included infliximab (nϭ6) or etanercept (nϭ6; Table 2 ).
Metabolic Control
An improvement in the overall glycemic control was observed in all patients after islet transplantation ( Figure 1 ). Overall, there was a significant reduction from baseline (141.1Ϯ14.4 mg/dL) of fasting glycemic values after transplantation (overall reduction: 40.7Ϯ16.5 mg/dL, Pϭ0.01); the mean reduction was 42.1Ϯ14.3 and 46.5Ϯ15.1 mg/dL up to 24 and 36 months, respectively (PՅ0.03; Figure 1A) . A significant reduction in A1c was observed when comparing overall posttransplant values to baseline (baseline: 8.2Ϯ1.3%; mean overall reduction 1.95Ϯ0.31%, PϽ0.0001); this was associated with a mean reduction of 2.21Ϯ0.31%, 1.88Ϯ0.36% and 1.76Ϯ0.28% (PϽ0.0001 vs. baseline) up to 12, 24, and 36 months after transplantation ( Figure 1B) .
The 90-min glucose values during MMTT showed a significant improvement in all patients, when comparing baseline (317.1Ϯ25.7 mg/dL) to posttransplant responses (mean reduction: 147.8Ϯ26.5 mg/dL overall; 167.7Ϯ29.3, 154.9Ϯ27.5, and 120.8Ϯ31.9 up to 12, 24, and 36 months, respectively; PϽ0.001; Fig. 1C) . Also, the 90-min C-peptide (MMTT) showed a significant improvement, when comparing baseline (Ͻ0.3 ng/mL) to posttransplant values (mean overall increase: 3.38Ϯ0.29 ng/mL; 3.01Ϯ0.20, 3.36Ϯ0.39, and 3.77Ϯ0.47 up to 12, 24, and 36 months, respectively; PϽ0.0001; Fig. 1D) .
In Pt. 6, complete islet graft loss occurred by 9 months after IAK. This patient experienced a serious adverse event (livedoid vasculitis requiring hospitalization), during which immunosuppression regimen was transiently reduced and then resumed to target after discharge. After resolution of this event, optimal islet graft function and metabolic control was observed at the 6-month visit. At subsequent visits, drugs trough levels were found to be below target, possibly because of nonadherence to the immunosuppressive therapy prescribed.
All metabolic parameters remained stable throughout the follow-up, despite reintroduction of exogenous insulin in patients developing graft dysfunction (nϭ6). Also basal CPGR (0.18Ϯ0.07, nϭ7) showed a statistically significant improvement in all patients after islet transplantation (estimate overall change: 1.17Ϯ0.16; 1.39Ϯ0.17, 1.12Ϯ0.10, and 1.01Ϯ0.34 at 12, 24, and 36 months, respectively; PϽ0.003).
All patients showed substantial reduction of insulin requirements after the first islet infusion (77.6Ϯ19.4% of baseline, nϭ7), with two patients (Pt. 1 and Pt. 2) achieving insulin independence with a single islet infusion ( Table 2 , Fig.  1E ). All remaining patients achieved insulin independence after the second infusion, except for Pt.7 who remained on exogenous insulin therapy with an initial 61% reduction of insulin requirement, which stabilized to 52% of baseline dose by 6 months posttransplantation (from 0.52 at baseline to 0.25 U/Kg/day at 18-month follow-up; Fig. 1E ). Overall, mean duration of insulin independence was 356Ϯ168 days after the last infusion (nϭ6). Exogenous insulin dose reduction was 79.0Ϯ21.6%, 55.5Ϯ35.6%, and 51.0Ϯ36.8%, at 1, 2, and 3 years after IAK, respectively.
Patient 5 received two islet infusions for a total of three islet preparations and was treated with triple immunosuppression (S,T,M). Drug trough levels were suboptimal for islet transplantation because of poor tolerability and side effects. This patient showed islet graft dysfunction after 1 year and lost function after 2 years of implantation, while kidney graft function remained stable. With the exception of Pt.7 who did not achieve insulin independence, the cumulative proportion of insulin-free patients showed that reintroduction of exogenous insulin was required in all patients within 19 months (Fig. 1F) . By contrast basal C-peptide remained detectable in the remaining six patients for the duration of the follow-up (Fig. 1F) . The remaining five patients had insulin requirements lower than before islet transplantation (baseline: 0.56Ϯ0.12 U/kg/day; most recent follow-up: 0.22Ϯ0.08 U/kg/day; mean follow-up 681Ϯ336 days). Notably, none of the patients experienced severe hypoglycemic episodes during follow-up, despite reintroduction of exogenous insulin (Table 3) .
Kidney Function
All patients showed stable kidney graft function before islet transplantation, classified as stage 2 (nϭ1) and 3 (nϭ6) by the National Kidney Foundation (Table 1) (41) . No significant changes in sCr or GFR were observed after islet transplantation in 6/7 patients ( Fig. 2A, B) . Four patients pre- sented with micro-albuminuria before islet transplantation, and 3 remained stable throughout follow-up, whereas Pt. 3 developed proteinuria 3 months after transplant (Ͼ500 mg/ 24 hr; Fig. 2C, D) . Of the 2 patients with normo-albuminuria at baseline: Pt. 1 showed progression towards micro-albuminuria (from 36 to 69 mg/24 hr) 2 years after IAK and remained stable thereafter (Fig. 2C) . Proteinuria was present in Pt. 6 at baseline and during follow-up (from 1.8 to 2.1 g/24 hr; Fig.  2C, D) . Introduction of angiotensin receptor blockers (ARB; 16 mg/day initially, then up to 64 mg/day) resulted in improvement of albuminuria and proteinuria in Pt.3 (Fig. 2C,  D) . Islet graft dysfunction and subsequent loss of C-peptide occurred at 9 months, in Pt. 6, as discussed above. Eighteen months later, kidney graft failure occurred.
Adverse Events
Infusion-related adverse events (AEs) were mild-tomoderate (NCI criteria, grade Ͻ3). They included acute chole- showing improvement in all patients after islet transplantation. Results of mixed meal tolerance tests are shown as 90-min glucose (C) and C-peptide values (D). These parameters significantly improved (PϽ0.0001) after islet transplantation in all patients when comparing pretransplant values to those obtained from all patients posttransplant. Stable control was observed in all but 2 patients who experienced islet graft rejection 9 (Pt. 6, ▫) and 24 months (Pt. 5, Ⅲ) after transplantation. The benefits of the transplant on metabolic control persisted despite reintroduction of insulin in all remaining patients. Daily insulin requirements over time after the last islet infusion are shown in individual patients (E). The number zero in the figure indicates achievement of insulin independence. F, Graft function in the study population assessed as persistence of measurable levels of basal C-peptide (Ͼ0.3 ng/mL; ⅙) and independence from exogenous insulin after islet transplantation (•). Censored patients are shown (ϩ).
cystitis (nϭ1) and pleural effusions (nϭ2) that resolved satisfactorily without sequelae (Table 3) . None of the patients experienced severe hypoglycemic episodes after IAK, even when exogenous insulin was required to maintain adequate glycemic control. Notably, these patients went from an average of 3 episodes (range 0 -10) in the year preceding the transplant to 0 episodes after transplantation. The AE at follow-up (Table 3) included development of anemia and/or worsening of preexisting anemia (nϭ6, grade 1-2). All patients responded to medical treatment without requiring blood transfusions. Four patients developed severe neutropenia (grade 4) that was successfully treated with filgrastim with normalization of ANC. All patients maintained adequate lipid control on statins (nϭ6) throughout the follow-up. Thirteen serious AEs were recorded according to NCI criteria (grade 2-4), or requirement of hospitalization and/or prolongation of hospitalization (Table 3 ). All AEs were successfully treated, and patients recovered satisfactorily. All patients showed previous exposure to Epstein-Barr virus (EBV) at baseline. Two cases (Pt. 3 and Pt. 4) of EBV reactivation were detected by PCR 33.6Ϯ9.6 months after last islet infusion requiring valgancyclovir treatment for up to 4 months; both patients recovered satisfactorily and maintained islet graft function without development of posttransplant lymphoproliferative disease. Only 2 patients (Pt. 2 and Pt. 4) had negative serology for CMV at baseline and remained negative throughout the follow-up.
Pt.1 had chronic hepatitis C virus (HCV) with normal liver function tests and a Grade 1 Stage II changes on a liver biopsy before IAK (preIAK viremia not done). Insulin independence was maintained for 281 days after IAK. He developed reactivation two years after IAK, which coincided with an attempt of conversion to MMF ϩ sirolimus maintenance due to 
a National Cancer Institute criteria (version 3.0B). b Procedure-related. c Three independent episodes requiring hospitalization in the same patient.
tacrolimus neurotoxicity. Elevation of liver function tests (up to 10-fold greater than normal levels) and a ϳ2-fold increase on immunosuppressive levels were associated with high PCR HCV titers (up to 2ϫ10 7 copies/mL). Liver biopsy was similar than pretransplant, showing focal and minimal portal inflammation, macrovesicular steatosis with absence of fibrosis. No specific treatment for HCV was given due to concerns of kidney and islet graft rejection (22, 44) . Immunosuppression doses (S-T) were reduced and levels maintained within target ranges. The patient remained clinically and metabolically stable.
Quality of Life
An overall improvement in QOL was observed after islet transplantation using objective measurements and psychometric questionnaires (3). After transplantation, DQOL impact and worry scores were significantly improved, when comparing baseline with overall posttransplant data (Pϭ 0.002 and Pϭ0.006, respectively; Table 4 ). After 12 months follow-up, DQOL scores for satisfaction, impact and worry significantly ameliorated, when compared with baseline, and the two latter persisted up to 24 months (Table 4) . Assessment of HSQ 2.0 showed improvement of all parameters, with a significant difference in mental health up to 24 months, when compared to baseline (Pϭ0.038; Table 4 ).
PRAs and Autoantibodies
All subjects had negative PRA before islet transplantation. Five patients remained PRA-negative during follow-up (confirmed by ELISA and/or flow technique). Patient 3 developed PRAϩ (HLA-I: 29%, HLA-II: 43%) while on immunosuppression 1 year after the second islet graft infusion and remained PRAϩ thereafter. This patient maintains stable islet and kidney graft function under target through levels of immunosuppression at Ͼ2 months from last PRAϩ. Six months after islet implantation, Pt. 6 developed HLA-I PRAϩ after reduction of immunosuppression because of complications requiring hospitalization. This patient did not adhere to protocol losing islet function (9 months postIAK) and later also kidney graft function (ϳ18 months later). Complete islet function loss occurred 24 months after transplant in Pt. 5, and she remains PRA-negative.
All patients were negative for autoantibodies pretransplant and remained negative during follow-up for GAD-65 (nϭ7) and IA2 (nϭ6). One patient (Pt.4) resulted positive for IA2 pretransplant and continued to be positive at all the posttransplant time points assessed (Baseline vs. postIAK ratio: 14.6 and 25.8, respectively), without any observed impact on islet graft function.
DISCUSSION
Achieving stable glycemic control in patients with T1DM is highly desirable to prevent long-term diabetic complications (45) . In patients with T1DM with ESRD bearing kidney allografts, optimal metabolic control is associated with improved longevity of the graft (11) (12) (13) (14) (15) (16) (17) . Moreover, the beneficial effects of ␤-cell replacement therapy in patients bearing a kidney graft, in terms of patient and graft survival, have been demonstrated (11) (12) (13) (14) (15) (16) (17) .
The success rate of initial IAK and SIK trials performed in the 1980s and 1990s was somehow limited (21) . In partic- ular, the use of immunosuppressive regimens based on the kidney transplant protocol with calcineurin-inhibitors and steroids might have contributed to the impairment of islet graft function (46, 47) and the increased metabolic demand (48) . Nonetheless, steady progress has been reported in the field of islet transplantation over the years after implementation of improved methods for human islet isolation (29) , purification (31) and of refined recipient's peri-transplant management (49, 50) . The availability of powerful immunosuppressive drugs and novel protocols specifically designed for islet transplantation has shown that insulin independence and prolonged graft survival can be achieved in recipients of ITA (7, 10, 51) . The substantial benefits of ␤-cell replacement are: (1) improvement of metabolic control, (2) prevention of severe hypoglycemic episodes even when exogenous insulin is required with (3) improvement in QOL and (4) reduction of long-term complications (3, 7, 52, 53) .
The effectiveness of the Edmonton protocol (5, 7, 8, 25 ) also has been demonstrated in patients undergoing SIK (27) . In IAK recipients, the need for modification of the immunosuppressive regimen already in place for the kidney graft represents a potential risk. Initial pilot reports have shown that conversion of patients bearing an allogeneic kidney to SϩT is safe and does not compromise kidney graft function and survival (23) . The safety and efficacy of IAK protocols using SϩT as maintenance therapy is confirmed by our study that extends previous reports (26) . Other Centers have reported conversion to steroid-sparing, sirolimus-tacrolimus protocols at the time of IAK (23, 26) associated with kidney graft rejection in one case (26) . Our protocol required conversion to SϩT maintenance regimen at least 6 months before IAK to evaluate its effects on kidney graft survival. At the time of IAK, greater target trough levels of immunosuppression were aimed as per protocol (Edmonton-like) and adjusted on an individual basis depending on tolerability and side effects. Two patients were maintained on triple immunosuppression (S,T,M) as the result of low tolerability of tacrolimus, allowing the maintenance of lower trough levels. One of these patients showed islet graft loss at 18 months after IAK, probably because of suboptimal immunosuppressive levels. Steroid avoidance was not a prerequisite in our trial and low doses were maintained in three cases in which the effects on overall graft survival cannot be discerned at this point (48) .
All patients showed graft function with significant improvement of metabolic control and reduction of insulin requirements, similarly to what has been reported for ITA (7, 10) . Insulin independence was achieved in 6/7 patients (85.7%), one with a single islet infusion and another with an infusion of two islet preparations. Patients 6 and 5 lost islet graft function by 9 and 24 months, respectively. Reduction of immunosuppression (nϭ2) and possible nonadherence (nϭ1), may have contributed to the observed outcome. All remaining patients (85.7% at 12 months) maintained graft function during the follow-up (up to 36 months), although insulin independence was only 30% at 12 months and all patients restarted exogenous insulin by 19 months. When compared with previous IAK, SIK, and ITA reports, our trial showed lower duration of insulin independence (7, 8, 26, 27) . This could be attributable to the relative wide heterogeneity of our patient population that included three recipients of previous pancreatic grafts and one of two subsequent livingrelated kidneys. Sensitization of islet graft recipients and PRAϩ have been associated with worse clinical outcome (54, 55) . In our series, all patients had PRA-negative at baseline, whereas PRAϩ was observed after IAK in two patients: Pt. 6 showed PRAϩ followed lowering/discontinuation of immunosuppression, whereas in Pt. 3 PRAϩ was not associated with any clinical event and it did not affect islet and kidney graft functions. Interestingly, Pt. 5 remained PRA-negative during follow-up despite complete loss of islet function with stable kidney allograft function. No association of auto-antibodies levels (GAD65 and IA2) with graft survival was observed. These data may suggest that the progressive loss of islet graft function in our series was not associated with allosensitization and/or autoimmunity, and that additional factors (i.e. metabolic demand, chronic toxicity of immunosuppressive drugs, etc.) could have played a role in this phenomenon (56) . Sustained graft function measured by basal and stimulated C-peptide levels was observed in our patient population, which is comparable to that reported for recent ITA trials (4, 5, 7, 8, 25) . Notably, persistent C-peptide after IAK has been associated with prolonged benefit of islet transplantation in patients with T1DM and ESRD, and particularly prevention of severe hypoglycemia up to 14 years after islet infusion (19, 22) . The beneficial effects of sustained C-peptide production have been postulated (12) (13) (14) (15) (16) . Notably, no episodes of severe hypoglycemia were recorded in our trial, despite reintroduction of insulin. The insulin required to maintain adequate metabolic control (assessed by A1c, 90-min C-peptide and glucose values after MMTT) was substantially reduced in all patients, when compared to baseline. Also, C-peptide values significantly increased from baseline. Kidney function remained stable in 6 of 7 patients patients with no remarkable changes in sCr and GFR. Also, albuminuria remained stable, with the exception of one patient showing progression from micro-to macro-albuminuria and sustained proteinuria (1.5 g/24 hr) requiring ARB treatment that resulted in a measurable improvement of proteinuria.
AEs associated with the transplant procedure and immunosuppressive drugs were similar in frequency and severity to that reported in other trials and resolved satisfactorily with medical treatment (57) . The severity of the adverse events in most of the cases was associated with the early peritransplant period when target trough levels of sirolimus were higher (12-15 ng/mL) and ameliorated after dose reduction. Two cases of EBV reactivations were observed without occurrence of PTLD. No CMV disease was observed (37) .
One patient developed HCV reactivation 18 months after IAK. This was characterized by sudden increase of liver enzymes and concomitant high trough levels of immunosuppression. Pretransplant HCV titers were not taken, but normal liver function tests and Grade 1/Stage II liver disease indicated a clinically stable pattern. Liver biopsy performed after HCV reactivation showed unchanged histolopathological features from pretransplant, and the consensus at that time was to reduce immunosuppression and hold antiviral treatment due to concerns of kidney and islet graft rejection. Indeed, greater incidence of diabetes (58) or kidney rejection have been reported in patients with HCV after interferonalpha therapy (44) . Similarly, we previously observed islet rejection after interferon treatment in a SIK recipient (22) . At the latest follow-up, liver function tests remain 2-fold the upper limit of normality and viremia is still present, but the patient maintains stable metabolic control and kidney function. On the basis of our observations, we would consider positive HCV as a contraindication for intrahepatic islet transplantation because: (1) HCV reactivation after induction or changes in immunosuppression during follow up is possible; (2) it is unclear the effect of the inflammatory milieu on islet function; (3) HCV is associated with severe insulin resistance and (4) in cases of reactivation, there is a potential risk for islet and/or kidney graft loss after anti-viral treatment (22, 44, 59) .
Our study also showed an amelioration of objective psychometric measures of QOL in IAK recipients. This is in agreement with previous observations (3, 60, 61) . Notably, the DQOL impact and worry scores showed sustained improvement associated with an islet transplant, despite the need for exogenous insulin to maintain adequate metabolic control. This may reflect the lack of severe hypoglycemia associated with an islet graft that has been consistently observed in previous trials (19, 52, 60) .
CONCLUSIONS
Although insulin independence after IAK was shorterlived than that reported in recent ITA trials using similar protocols, improvement in metabolic control was invariably observed in the absence of severe hypoglycemia and persisted even when insulin therapy was resumed. The direct consequence of these benefits is reflected in a significant improvement in QOL. Close follow-up after IAK to monitor immunosuppressive regimen levels/toxicity is necessary to minimize side effects that could jeopardize patient's compliance. Achieving stable metabolic control in patients with T1DM should be the ultimate goal of any therapeutic approach. Our data suggests that in patients bearing a kidney allograft, stable metabolic control can be accomplished by transplantation of pancreatic islets. The effect of IAK on chronic diabetes complications is still to be determined in larger cohorts of patients and randomized long-term prospective studies.
